Drug Profile
Research programme: chimeric antigen T-cell therapies - bluebird bio
Alternative Names: CAR T-cell therapy - bluebird bioLatest Information Update: 23 Aug 2023
Price :
$50
*
At a glance
- Originator bluebird bio
- Developer bluebird bio; Seattle Childrens Research Institute
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Diffuse large B cell lymphoma; Haematological malignancies; Solid tumours
Most Recent Events
- 23 Aug 2023 Discontinued - Preclinical for Acute myeloid leukaemia in USA (Parenteral)
- 23 Aug 2023 Discontinued - Preclinical for Diffuse large B cell lymphoma in USA (Parenteral)
- 23 Aug 2023 Discontinued - Preclinical for Haematological malignancies in USA (Parenteral)